I have had superior mesenteric artery syndrome for six years without a nasogastric (NG) tube; how do I arrange for nasogastric/nasojejunal tube placement?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How to Arrange Nasogastric/Nasojejunal Tube Placement for Superior Mesenteric Artery Syndrome

For superior mesenteric artery syndrome (SMAS) after six years without tube placement, you need a nasojejunal (NJ) tube placed beyond the duodenal obstruction, not a standard nasogastric tube, and this should be done via endoscopic or fluoroscopic guidance by gastroenterology or interventional radiology.

Why Nasojejunal Rather Than Nasogastric

In SMAS, the third portion of the duodenum is compressed between the superior mesenteric artery and aorta 1, 2, 3. A standard NG tube that terminates in the stomach will not bypass this obstruction and will fail to provide adequate decompression or nutrition 1. You specifically need post-pyloric access into the jejunum to deliver nutrition beyond the point of compression 3.

Step-by-Step Approach to Getting the Tube Placed

1. Contact Gastroenterology or Interventional Radiology

  • Request consultation for endoscopic or fluoroscopic-guided nasojejunal tube placement 4, 5
  • Specify that you have SMAS and need post-pyloric access for both decompression and enteral nutrition
  • Success rates exceed 90% with guided placement versus 56-92% with blind bedside attempts 5

2. Pre-Procedure Requirements

Before the procedure, you'll need 5:

  • INR testing (required for all patients)
  • Activated PTT if you're on heparin
  • Single dose of first-generation cephalosporin antibiotic immediately before placement 4

3. Placement Technique Options

The most effective methods are 5:

Endoscopic-guided placement:

  • Endoscope advanced into distal duodenum/proximal jejunum
  • Guide wire passed through biopsy channel into jejunum
  • Endoscope removed, feeding tube passed over wire into small intestine
  • Success rate >90% 5

Fluoroscopic-guided placement:

  • Similar technique using fluoroscopy for visualization
  • Equally effective with >90% success rate 5

4. Confirmation Before Use

  • Mandatory radiographic confirmation of tube position before initiating feeds 5
  • Bedside auscultation is unreliable and can miss malposition (lung, pleural cavity, coiled in esophagus) 5

Important Considerations for SMAS Specifically

Short-Term vs Long-Term Access

  • NJ tubes are appropriate for <4 weeks of anticipated use 4
  • Given your six-year history, you may ultimately need percutaneous endoscopic gastrojejunostomy (PEG-J) or direct percutaneous endoscopic jejunostomy (DPEJ) for long-term access 4, 1
  • One case report showed successful transition from NG to PEG-J in SMAS with symptom resolution 1

Tube Securing

  • Request nasal bridle placement to prevent dislodgement, as 40-80% of nasoenteric tubes become dislodged with standard taping 5
  • This is critical given the difficulty of NJ placement and your chronic condition

Feeding Considerations

  • Small bowel feeding requires reduced and cycled feeding rates to prevent dumping syndrome 4
  • Continuous pump feeding is preferred over bolus for jejunal access 4

Common Pitfalls to Avoid

  1. Don't accept a standard NG tube - it won't bypass the duodenal obstruction in SMAS
  2. Don't attempt blind bedside placement - success rates are poor for NJ tubes and you'll waste time with repeated failures 5
  3. Don't use weighted tubes - unweighted tubes have higher success rates for spontaneous small bowel passage 5
  4. Don't start feeding without radiographic confirmation - malposition can cause serious complications 5

If Conservative Management Fails

Recent literature emphasizes that if nutritional rehabilitation via NJ tube fails to restore mesenteric fat pad and resolve symptoms, duodenojejunostomy is the preferred surgical approach with significant symptom reduction and improved quality of life 3. After six years, you should discuss with your gastroenterologist whether surgical intervention might be more definitive than continued tube management 6, 3.

Practical Next Steps

  1. Call gastroenterology or interventional radiology this week
  2. Explain you have SMAS diagnosed six years ago
  3. Request: "I need endoscopic or fluoroscopic-guided nasojejunal tube placement for enteral nutrition and decompression"
  4. Ask about transition plan to PEG-J if symptoms persist beyond 4 weeks 4

Related Questions

When should a patient with superior mesenteric artery (SMA) syndrome require nasogastric (NG) tube placement?
Can a nasogastric tube be reconnected after a small‑bowel follow‑through study if the imaging has not yet been interpreted?
Should a nasogastric (Ryle’s) tube be placed for decontamination in a patient who ingested naphthalene?
What is the differential diagnosis for a young woman with headaches, nausea, and vomiting that occur immediately after eating for the past three months, accompanied by rapid weight loss?
In a patient with dilated large and small bowel loops with air‑fluid levels and hair‑pin turns suggestive of ileus or enterocolitis, is nasogastric (NG) decompression appropriate?
When should the amikacin trough level be obtained?
In a 30-year-old female (~102 lb) presenting with alcohol‑withdrawal tremor, nausea, anxiety, tachycardia and hypotension after binge drinking, who has received lorazepam (Ativan) 2 mg PO, chlordiazepoxide 50 mg PO, lorazepam 2 mg IV, 1 L normal saline, 2 L lactated Ringer’s, and ondansetron (Zofran) 4 mg IV twice with improvement to a Glasgow Coma Scale of 14, what is the best next step in management?
What randomized controlled trials support the use of high‑intensity statins for preventing recurrent ischemic stroke in adults?
Present the PICO format for each of the following trials: (1) SPARCL – adults aged 45‑80 years with a recent ischemic stroke or transient ischemic attack, LDL‑C 100‑190 mg/dL, no known coronary artery disease, peripheral arterial disease, atrial fibrillation, prosthetic heart valves, or significant mitral stenosis; intervention atorvastatin 80 mg daily versus placebo; outcome first recurrent stroke (ischemic or hemorrhagic). (2) Treat‑Stroke‑to‑Target – adults aged 18‑85 years with an acute cerebral infarction within 3 months or a high‑risk transient ischemic attack; intervention high‑intensity statin therapy (atorvastatin 80 mg or rosuvastatin 20 mg) titrated to LDL‑C <70 mg/dL with ezetimibe added if needed versus moderate‑intensity statin therapy (simvastatin 20‑40 mg or pravastatin 40 mg) titrated to LDL‑C 90‑110 mg/dL; outcome major cardiovascular events including recurrent ischemic stroke, myocardial infarction, or vascular death.
What is the recommended treatment for renal potassium loss?
In complete (third-degree) heart block, what is the typical atrial rate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.